ArticleJournal of breast cancer2017
Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry.
Article in Journal of breast cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.Nature communications · 2025Trial
- High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.Journal of surgical oncology · 2022Trial
- Accurate assessment of surgical HER2-low status based on core needle biopsy data of breast cancer.Diagnostic and prognostic research · 2026Article
- Hybrid [Bioengineering (Basel, Switzerland) · 2026Article
- AI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screening.Breast cancer research : BCR · 2026Article
- Feasibility, reliability, and clinical value of genomic assay on pre-therapeutic biopsy for endocrine receptor-positive HER2-negative early breast cancer.Frontiers in oncology · 2026Review
- Post-Surgical Reassessment of Breast Cancer IHC: Concordance, Δ-Metrics, and Treatment-Relevant Reclassification.Diagnostics (Basel, Switzerland) · 2025Article
- Concordance of Oncotype DX Breast Recurrence Score Assay Results Between Paired Core Needle Biopsy and Surgical Excision Specimens in Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Early-Stage Breast Cancer.JCO precision oncology · 2025Article
- Article
- MRI features of breast cancer immunophenotypes with a focus on luminal estrogen receptor low positive invasive carcinomas.Scientific reports · 2024Article
- Core Needle Biopsy Accuracy for Androgen Receptor Expression in Invasive Breast Cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023Article
- Differences in Tumour Aggressiveness Based on Molecular Subtype and Race Measured by [Diagnostics (Basel, Switzerland) · 2023Article
- Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature.Breast cancer research and treatment · 2023Review
- Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients.Scientific reports · 2023Article
- Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population.Breast cancer research and treatment · 2023Article
- Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.Cancer medicine · 2022Article
- Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.NPJ breast cancer · 2022Article
- Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.Breast cancer research and treatment · 2022Article
- CD8Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated the concordance between core needle biopsy (CNB) and surgical specimens on examining intrinsic biological subtypes and receptor status, and determined the accuracy of CNB as a basic diagnostic method.
methodsWe analyzed breast cancer patients with paired CNB and surgical specimen samples during 2014. We used monoclonal antibodies for nuclear staining, and estrogen receptor (ER) and progesterone receptor (PR) status evaluation. A positive test was defined as staining greater than or equal to 1% of tumor cells. Human epidermal growth factor receptor 2 (HER2) was graded by immunohistochemistry and scored as 0 to 3+ according to the recommendations of the American Society of Clinical Oncology/College of American Pathologists. Ki-67 immunostaining was performed using the monoclonal antibody Ki-67, and the results were divided at 10% intervals. The cutoff value for high Ki-67 was defined as 20%. Concordance analysis of ER, PR, HER2, Ki-67, and five intrinsic biological subtypes was performed on CNB and surgical specimens. Statistical analysis for concordance was calculated using κ-tests.
resultsWe found very good agreement for ER and PR with a concordance of 96.7% for ER (κ=0.903), and 94.3% for PR (κ=0.870). HER2 and Ki-67 showed concordance rates of 84.8% (κ=0.684) and 83.5% (κ=0.647), respectively, which were interpreted as good agreement. Five subgroups analysis showed 85.8% agreement and κ-value of 0.786, also indicating good agreement.
conclusionCNB showed high diagnostic accuracy compared with surgical specimens, and good agreement for ER, PR, HER2, and Ki-67. Our findings reaffirmed the recommendation of CNB as an initial procedure for breast cancer diagnosis, and the assessment of receptor status and intrinsic biological subtypes to determine further treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.